Ignite Creation Date:
2024-07-17 @ 11:35 AM
Last Modification Date:
2024-10-26 @ 3:32 PM
Study NCT ID:
NCT06461377
Status:
RECRUITING
Last Update Posted:
2024-06-21
First Post:
2024-03-01
Brief Title:
The Ameliorative Effects of GLP-1RA on Diabetic Cardiac Autonomatic Neuropathy
Sponsor:
The First Affiliated Hospital with Nanjing Medical University
Organization:
The First Affiliated Hospital with Nanjing Medical University
Study Overview
Official Title:
The Ameliorative Effects of GLP-1RA on Diabetic Cardiac Autonomatic Neuropathy
Status:
RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Diabetic cardiac autonomic neuropathy DCAN is a common chronic complication that reduces survival in patients with diabetes Epidemiological surveys have shown that the prevalence of DCAN is 25-75 in people with type 2 diabetes The onset of DCAN is insidious and easy to be ignored in the early stage With the progression of the disease the following clinical symptoms gradually appear including reduced heart rate variability exercise intolerance resting tachycardia orthostatic hypotension painless myocardial infarction and even sudden death which seriously endanger the life and health of type 2 diabetes patients Existing literature has shown that glucagon-like peptide-1 receptor agonist GLP-1RA can improve diabetic peripheral neuropathy and diabetic cognitive dysfunction but there are few studies on improving diabetic autonomic neuropathy Insulin resistance is an important risk factor for DCAN Patients with type 2 diabetes are characterized by insulin resistance and GLP-1RA is recognized as a drug to improve insulin resistance and control blood sugar in patients with diabetes In this study GLP-1RA was used to intervene patients with type 2 diabetes and the changes in blood sugar control and insulin resistance status of patients were followed up Special attention was paid to the improvement of autonomic neuropathy in diabetic patients
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None